Episode 3a: Learn About Bexagliflozin for Diabetic Cats! 🐱

✨ Here we are again! ✨
This time with a special request from clients and followers who want help navigating diabetes mellitus and the new medications on the market.

 Episode 3a kicks off our exploration of Bexaglifozin, with a second episode dedicated to Velaglifozin coming soon!
🔗 You can access:
A summary for quick insights: see below
A detailed discussion here:

📚 Study Summary
𝘚𝘢𝘧𝘦𝘵𝘺 𝘢𝘯𝘥 𝘌𝘧𝘧𝘦𝘤𝘵𝘪𝘷𝘦𝘯𝘦𝘴𝘴 𝘰𝘧 𝘵𝘩𝘦 𝘚𝘰𝘥𝘪𝘶𝘮-𝘎𝘭𝘶𝘤𝘰𝘴𝘦 𝘊𝘰𝘵𝘳𝘢𝘯𝘴𝘱𝘰𝘳𝘵𝘦𝘳 𝘐𝘯𝘩𝘪𝘣𝘪𝘵𝘰𝘳 𝘉𝘦𝘹𝘢𝘨𝘭𝘪𝘧𝘭𝘰𝘻𝘪𝘯 𝘪𝘯 𝘊𝘢𝘵𝘴 𝘕𝘦𝘸𝘭𝘺 𝘋𝘪𝘢𝘨𝘯𝘰𝘴𝘦𝘥 𝘸𝘪𝘵𝘩 𝘋𝘪𝘢𝘣𝘦𝘵𝘦𝘴 𝘔𝘦𝘭𝘭𝘪𝘵𝘶𝘴
𝘏𝘢𝘥𝘥 𝘦𝘵 𝘢𝘭., 𝘑 𝘝𝘦𝘵 𝘐𝘯𝘵𝘦𝘳𝘯 𝘔𝘦𝘥. 2023 𝘔𝘢𝘺-𝘑𝘶𝘯;37(3):915-924. 𝘥𝘰𝘪: 10.1111/𝘫𝘷𝘪𝘮.16730.
💡 Background
This study evaluates the safety and effectiveness of bexagliflozin in cats newly diagnosed with diabetes mellitus.
💡 Aim
1️⃣ Assess the safety profile of bexagliflozin
2️⃣ Evaluate its efficacy in improving glycemic control
💡 Materials and Methods
🐾 Newly diagnosed diabetic cats confirmed via clinical signs, hyperglycemia, and glucosuria
💊 Cats received oral bexagliflozin, with monitoring for blood glucose, fructosamine levels, clinical signs, and adverse events
💡 Key Findings
✔️ 𝘌𝘧𝘧𝘪𝘤𝘢𝘤𝘺: Improved glycemic control in 84% of cats
✔️ 𝘊𝘭𝘪𝘯𝘪𝘤𝘢𝘭 𝘚𝘪𝘨𝘯𝘴: Substantial improvement in diabetes-related signs (polyuria, polydipsia, polyphagia)
✔️ 𝘚𝘢𝘧𝘦𝘵𝘺: Generally well-tolerated; some adverse events (vomiting, diarrhea, anorexia, lethargy, dehydration) noted
⚠️ 𝘚𝘦𝘳𝘪𝘰𝘶𝘴 𝘈𝘥𝘷𝘦𝘳𝘴𝘦 𝘌𝘷𝘦𝘯𝘵𝘴: Rare cases of diabetic ketoacidosis and euglycemic diabetic ketoacidosis emphasize the need for close monitoring
💬 Conclusion
Bexagliflozin is a promising option for newly diagnosed diabetic cats, but careful patient selection and monitoring are critical.

𝘋𝘪𝘴𝘤𝘭𝘢𝘪𝘮𝘦𝘳:
Please remember this is a brief summary. For a comprehensive understanding of the study’s findings and implications, please refer to the full-text article: doi: 10.1111/jvim.16730